Trial Profile

A Phase 1b, Open-Label, Pharmacokinetic/Pharmacodynamic, Ascending-Dose Safety Lead-In Trial of Trans Sodium Crocetinate (TSC) in Hospitalized Hypoxemic COVID-19 Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Transcrocetinate sodium (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; Hypoxaemia
Focus Adverse reactions; Proof of concept
Sponsors Diffusion Pharmaceuticals

Most Recent Events

10 May 2021 According to a Diffusion Pharmaceuticals media release, data from this stud were reviewed by an independent Safety Monitoring Committee (SMC).
10 May 2021 Final results presented in a Diffusion Pharmaceuticals media release.
16 Feb 2021 According to a Diffusion Pharmaceuticals media release, evaluation of the secondary endpoint data is ongoing and will be available early in the second quarter of 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com